A note for UK readers

This page explains Australia’s system. Its licences, funding rules and prescribing criteria do not determine access in the UK.

Does a PBAC recommendation make a prescription subsidised immediately?

No. A recommendation is part of the process; the final PBS listing, indication and effective date must be checked.

Registration is evolving

The TGA describes Wegovy and Mounjaro among medicines approved for weight management. In November 2026 it also published approval of Wegovy tablets. A newly registered formulation should not be assumed to be commercially available at every pharmacy.

Check the exact subsidy

PBAC advised a conditional Wegovy listing for a defined cardiovascular-disease and obesity group. That recommendation should not be restated as general PBS coverage for weight loss. Confirm the live PBS position and the proposed indication with the pharmacist or prescriber.

A private quote needs more detail

Ask for the AUD cost of the actual prescribed pack, dispensing and medical reviews. Avoid assuming that diabetes-related subsidy rules apply to obesity treatment, or that a new formulation will have the same price as an existing injection.

What carries across to a UK comparison

The distinction between approval, funding advice and implemented subsidy is useful in the UK too. Australian decisions themselves do not create NHS access. For UK treatment, use MHRA information and the relevant NHS or private-care pathway rather than Australian eligibility or AUD prices.

Keep these four questions separate

Access

Australian prescription and TGA-registration context

Funding

Verify live PBS indication; recommendation is not listing

Cost context

AUD subsidy and private charges are not UK prices

Regulatory source

Therapeutic Goods Administration

Compare health systems ↗
Follow the evidence

Sources & further reading

Sources checked . These links support the information above; they do not imply endorsement of this website.

  1. TGA: new diabetes and weight-loss medicines
  2. TGA: Wegovy tablet registration decision, November 2026
  3. PBAC: advice on access to GLP-1 obesity treatments
A note on this guide

Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.

Read our editorial standards →